Trump announces 100% chip tariff as Apple ups U.S. investment
AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), whose stock has surged over 320% year-to-date according to InvestingPro data, announced Monday the appointment of Jeff Fried to its Advisory Board.
Fried, who currently serves as Director of Platform Strategy and Innovations for InterSystems, brings over 25 years of experience in healthcare data infrastructure and AI innovation. He has previously held CTO positions at Teloquent, Empirix, and BA Insight, along with product leadership roles at FAST Search and Microsoft. The appointment comes as ImmunoPrecise, with its current market capitalization of $79 million, maintains a healthy financial position with liquid assets exceeding short-term obligations.
In his current role at InterSystems, Fried helps develop data solutions for healthcare and life sciences environments. He has supported the company’s LENSai platform through BioStrand’s partnership with InterSystems to integrate vector search capabilities.
"We are excited to welcome Jeff to our Advisory Board at a time when our vision for a scalable, bio-native AI infrastructure is rapidly becoming a reality," said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies.
Fried commented on his appointment: "LENSai is one of the most exciting AI platforms I’ve encountered in the life sciences space. It solves a foundational problem—making biological data interoperable and computationally accessible at scale."
ImmunoPrecise Antibodies describes itself as a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery. The company’s platforms are designed to enable reasoning across sequence, structure, function, and scientific literature for applications in drug discovery, diagnostics, and vaccine design.
This information is based on a company press release statement. InvestingPro analysis indicates the company is currently fairly valued, with 7 additional ProTips available covering growth, profitability, and momentum metrics. Get access to the comprehensive Pro Research Report, part of InvestingPro’s coverage of 1,400+ US equities, for deeper insights into IPA’s financial health and market position.
In other recent news, ImmunoPrecise Antibodies Ltd. has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. The company achieved this by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. Additionally, H.C. Wainwright has reiterated its Buy rating for ImmunoPrecise, maintaining a price target of $5.00, following the announcement of two novel AI-based drug discoveries targeting obesity and infectious diseases. These developments are seen as potential validation for the company’s AI platform, acquired through the March 2022 purchase of BioStrand. Furthermore, ImmunoPrecise has made a significant breakthrough in identifying a universal dengue vaccine target using its LENSai platform, which could lead to a vaccine effective against all four dengue virus serotypes. This discovery was achieved through in silico analysis, highlighting the potential of AI in biological research. The company plans to extend its AI-driven vaccine design platform to other infectious diseases and oncology applications. These recent developments reflect ImmunoPrecise’s commitment to advancing drug discovery through innovative AI technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.